AI assistant
Summit Therapeutics Inc. — Director's Dealing 2026
Jan 7, 2026
30436_dirs_2026-01-06_d0bcf98b-6594-4c20-9a23-acd30edeb763.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2026-01-02
Reporting Person: Clark Kenneth A (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-01-02 | Stock Option (right to buy) | $17.52 | A | 35000 | Acquired | 2036-01-02 | Common Stock (35000) | Direct |
| 2026-01-02 | Stock Option (right to buy) | $17.52 | A | 17796 | Acquired | 2036-01-02 | Common Stock (17796) | Direct |
Footnotes
F1: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date.
F2: Not applicable.
F3: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date.
F4: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $155,900.